BioCentury | Feb 8, 2020
Product Development

Feb. 7 Product Development Quick Takes: Myriad tumbles on revenue miss; plus Verana, Sanofi, VIB, Coda, Blueprint

...therapy. Coda moves chemogenetic therapies close to clinic with Attenua acquisition Coda Biotherapeutics Inc. acquired Attenua Inc....
BioCentury | Jul 13, 2018
Financial News

Abingworth's BioVentures VII fund closes at $315M, exceeding target

...vaccine company Nouscom AG (Basel, Switzerland), participation in a series A round for cough company Attenua Inc....
BioCentury | Jul 13, 2018
Finance

Curating Abingworth

...for cancer vaccine company Nouscom AG and participation in a series A for cough company Attenua Inc. Allison...
BioCentury | Jul 9, 2018
Financial News

Abingworth closes BioVentures VII fund at $315M

...vaccine company Nouscom AG (Basel, Switzerland), participation in a series A round for cough company Attenua Inc....
BioCentury | May 4, 2018
Financial News

Attenua raises $35M series A

...Cough company Attenua Inc. (Mountain View, Calif.) raised $35 million in a series A round on April...
...by new investor Omega Funds. New investors Abingworth, OrbiMed Advisors and Redmile Group also participated. Attenua...
...NYSE:MRK) acquired in 2016 (see BioCentury, June 13, 2016) . Attenua Inc., Mountain View, Calif. Jaime De Leon Attenua Inc. Nicotinic...
BioCentury | Apr 30, 2018
Financial News

Cough company Attenua raises $35M series A, names CEO

...by new investor Omega Funds. New investors Abingworth, OrbiMed Advisors and Redmile Group also participated. Attenua...
...candidate after it missed the primary endpoint in a Phase II trial to treat ADHD. Attenua...
...& Co. Inc. (NYSE:MRK) acquired in 2016 (see BioCentury Extra, June 9, 2016) . Jaime De Leon Attenua Inc. Nicotinic...
BioCentury | Aug 22, 2016
Company News

Catalyst Biosciences, Attenua deal

...Catalyst will sell TC-5619, TC-6987 and TC-6683 (AZD1446) to Attenua for $1 million up front and...
...acetylcholine receptor alpha(4)beta(2) agonist, but the pharma discontinued development of the product to treat AD. Attenua...
...additional details (see BioCentury, Aug. 24, 2015). Catalyst Biosciences Inc. (NASDAQ:CBIO), South San Francisco, Calif. Attenua Inc....
Items per page:
1 - 7 of 7
BioCentury | Feb 8, 2020
Product Development

Feb. 7 Product Development Quick Takes: Myriad tumbles on revenue miss; plus Verana, Sanofi, VIB, Coda, Blueprint

...therapy. Coda moves chemogenetic therapies close to clinic with Attenua acquisition Coda Biotherapeutics Inc. acquired Attenua Inc....
BioCentury | Jul 13, 2018
Financial News

Abingworth's BioVentures VII fund closes at $315M, exceeding target

...vaccine company Nouscom AG (Basel, Switzerland), participation in a series A round for cough company Attenua Inc....
BioCentury | Jul 13, 2018
Finance

Curating Abingworth

...for cancer vaccine company Nouscom AG and participation in a series A for cough company Attenua Inc. Allison...
BioCentury | Jul 9, 2018
Financial News

Abingworth closes BioVentures VII fund at $315M

...vaccine company Nouscom AG (Basel, Switzerland), participation in a series A round for cough company Attenua Inc....
BioCentury | May 4, 2018
Financial News

Attenua raises $35M series A

...Cough company Attenua Inc. (Mountain View, Calif.) raised $35 million in a series A round on April...
...by new investor Omega Funds. New investors Abingworth, OrbiMed Advisors and Redmile Group also participated. Attenua...
...NYSE:MRK) acquired in 2016 (see BioCentury, June 13, 2016) . Attenua Inc., Mountain View, Calif. Jaime De Leon Attenua Inc. Nicotinic...
BioCentury | Apr 30, 2018
Financial News

Cough company Attenua raises $35M series A, names CEO

...by new investor Omega Funds. New investors Abingworth, OrbiMed Advisors and Redmile Group also participated. Attenua...
...candidate after it missed the primary endpoint in a Phase II trial to treat ADHD. Attenua...
...& Co. Inc. (NYSE:MRK) acquired in 2016 (see BioCentury Extra, June 9, 2016) . Jaime De Leon Attenua Inc. Nicotinic...
BioCentury | Aug 22, 2016
Company News

Catalyst Biosciences, Attenua deal

...Catalyst will sell TC-5619, TC-6987 and TC-6683 (AZD1446) to Attenua for $1 million up front and...
...acetylcholine receptor alpha(4)beta(2) agonist, but the pharma discontinued development of the product to treat AD. Attenua...
...additional details (see BioCentury, Aug. 24, 2015). Catalyst Biosciences Inc. (NASDAQ:CBIO), South San Francisco, Calif. Attenua Inc....
Items per page:
1 - 7 of 7